# BrightStar-2 (NCT06522360)

> Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

No report yet. It can be ordered.

- Drugs tested: brigatinib plus carboplatin plus pemetrexed; brigatinib
- Indication: ALK-positive advanced non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06522360
- Phase: PHASE2
- Status: WITHDRAWN
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Non-small Cell Lung Cancer
- Interventions: Brigatinib; Carboplatin; Pemetrexed
- Enrollment: 0
- Primary outcome: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

## Indexed commentary on BrightStar-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=brightstar-2-nct06522360